Two groundbreaking studies conducted at the Hospital for Special Surgery (HSS) have recently been honored with President’s Choice Awards by the American Society of Regional Anesthesia and Pain Medicine (ASRA), underscoring the institution’s pioneering role in pain management and orthopedic research. These studies not only push the boundaries of scientific understanding in post-surgical pain control but also have immediate implications for clinical practices that could transform patient outcomes on a global scale. The recognition further cements HSS’s reputation as a leader in developing innovative methods aimed at optimizing pain relief while minimizing reliance on opioids, a critical concern amid the ongoing opioid epidemic.
The first study, led by Alexandra Sideris, PhD, director of the Pain Prevention Research Center at HSS, focuses on the prevalence of cannabidiol (CBD) use among patients undergoing elective sports medicine surgeries involving the knee, shoulder, or hip. As the medical community seeks alternatives to opioid-based pain management due to their well-documented risks—including addiction and adverse side effects—CBD has emerged as a promising candidate. A non-intoxicating component of the cannabis plant, cannabidiol is federally legal and has gained traction as a potential adjunct or substitute for traditional analgesics. This survey study provides some of the earliest comprehensive data on how patients self-administer CBD in a surgical context and their subjective experiences regarding its efficacy.
Deployed between September and December 2024, the anonymous survey reached 470 patients scheduled for sports medicine procedures, yielding 159 responses. Remarkably, nearly 39% of respondents disclosed prior CBD use, with a significant proportion employing it on an “as-needed” basis, primarily for pain relief or sleep enhancement. The predominant form of consumption was gummies, with 44% purchasing these products at dispensaries. Notably, one-third of users reported that CBD was moderately to very helpful in managing their symptoms. Such findings not only highlight the widespread acceptance of CBD in populations vulnerable to postoperative pain but also emphasize the necessity for rigorous clinical trials to elucidate its pharmacodynamics and long-term effects within these contexts.
Dr. Sideris emphasized the ongoing nature of data collection at HSS, aimed at delineating the impact of CBD use on prescription medication patterns post-surgery. This initiative represents a crucial step toward integrating alternative pain management strategies into mainstream clinical pathways, potentially reducing opioid prescriptions and enhancing patient safety. The collaborative spirit underpinning this research was lauded as a reflection of HSS’s broader commitment to advancing patient care through scientific innovation.
The second awarded study investigates the relationship between surgical technique and postoperative opioid consumption in total hip replacement (THR) surgeries. Periklis Giannakis, MD, a research fellow at HSS, spearheaded this work, which analyzes data extracted from a multi-institutional database comprising nearly 100,000 THR cases. The meticulous comparative study evaluates three distinct surgical methods: manual, computer-assisted, and robotic-assisted techniques, focusing on their influence on opioid requirements during hospitalization.
Findings indicate that patients who underwent robotic-assisted THR required significantly less opioid analgesia compared to those treated with manual or computer-assisted approaches. This discovery aligns with the hypothesis that the precision afforded by robotic technology reduces soft tissue trauma, thereby diminishing acute postoperative inflammation and pain. Although the exact physiological mechanisms remain to be fully clarified, the association between minimally invasive robotic interventions and decreased opioid consumption offers compelling evidence favoring the adoption of advanced surgical technologies for enhanced postoperative recovery.
Dr. Giannakis underscored the imperative of optimizing pain control protocols that limit opioid exposure, given their implications for immediate functionality and long-term patient outcomes following hip replacement. The convergence of surgical innovation with pain management exemplifies a multidisciplinary approach to addressing the complex challenges inherent in musculoskeletal healthcare. Future investigations will dissect more granular data—such as the specific models of robotic and computer-assisted systems employed—with the aim of tailoring interventions to maximize analgesic effectiveness while curbing opioid dependence.
The recognition by ASRA through the President’s Choice Awards not only honors individual achievements but also highlights the collective endeavor of the Pain Prevention Research Center, the Department of Anesthesiology, and the Adult Reconstruction and Joint Replacement Service at HSS. Their ongoing collaborations embody a commitment to translational research that bridges the gap between bench science and clinical practice. Such efforts reflect a paradigm shift in orthopedic care, centered on precision medicine and patient-centric pain management strategies.
Hospital for Special Surgery occupies a distinguished position in the global medical landscape, consistently ranked as the top orthopedic hospital in the United States by U.S. News & World Report and acclaimed worldwide for its exemplary outcomes and innovation. Founded in 1863, HSS integrates clinical excellence with cutting-edge research and education, contributing to its reputation for having the lowest readmission and complication rates nationally within orthopedics. This institutional prowess provides a fertile environment for pioneering studies like those honored by ASRA, which continually push the envelope in improving musculoskeletal health.
Both studies embody the increasing recognition of the multifaceted nature of pain management, emphasizing the interplay of pharmacological alternatives, surgical technique, and patient-reported outcomes in shaping recovery trajectories. CBD’s role as a non-opioid analgesic adjunct and robotic-assisted surgery’s potential to minimize trauma illustrate emerging trends that could revolutionize standard postoperative protocols. These advancements resonate particularly powerfully in an era marked by heightened awareness of opioid-related risks and a societal imperative to find safer, more effective pain control modalities.
By integrating innovative research with clinical application, HSS is setting new standards for postoperative care, aiming to enhance quality of life for patients undergoing complex orthopedic procedures. The insights garnered from these studies herald a future in which pain prevention is proactive, personalized, and technologically sophisticated, reducing dependency on high-risk medications while promoting faster, safer recoveries. The potential ripple effects extend beyond individual patient experiences to influence healthcare systems and policy decisions on pain management practices worldwide.
Looking ahead, the collaborative teams at HSS plan to expand their research to include more nuanced assessments of how patient demographics, comorbidities, and surgical nuances intersect with emerging pain control modalities. The anticipation is that such comprehensive data will inform guidelines that are both evidence-based and adaptable to individual clinical scenarios. Ultimately, these efforts aspire to transform the paradigm of orthopedic postoperative care, rendering it more holistic, effective, and responsive to the needs of diverse patient populations.
In summary, the two President’s Choice Award-winning studies from HSS offer novel insights into pain management’s evolving landscape, highlighting cannabidiol’s emerging role and the advantages of robotic-assisted surgical techniques in decreasing opioid reliance. These findings not only contribute valuable data to the field but also reflect an ethos of innovation and patient-centered care that is critical in confronting current challenges in pain control. As these efforts continue to unfold, they promise to inspire further research and clinical advances, reinforcing HSS’s position at the forefront of musculoskeletal health innovation.
Subject of Research: People
Article Title: Not explicitly provided
News Publication Date: Not explicitly provided
Web References:
- https://epostersonline.com/asraspring2025/node/13?view=true
- https://epostersonline.com/asraspring2025/node/18?view=true
References:
- Sophia Madjarova BA, Arjun Khorana BS, William Chan MEng, Answorth Allen MD, Riley Williams MD, Benedict Nwachukwu MD, MBA, Alexandra Sideris PhD. “Prevalence of cannabidiol use in patients undergoing sports medicine procedures on the knee, shoulder, or hip: A survey study.”
- Periklis Giannakis, MD, Juliet E. Rowe, MPH, Lisa Reisinger, MD, Alex Illescas, MPH, Alexandra Sideris, PhD, Crispiana Cozowicz, MD, Junying Wang, MPH, Sophia T. Zhuang, Jiabin Liu, MD, PhD, Lazaros Poultsides, MD, PhD, Robert G. Marx, MD, Alejandro Gonzalez Della Valle, MD, Jashvant Poeran, MD, PhD, Stavros G. Memtsoudis, MD, PhD, MBA. “Opioid Consumption During Hospitalization Across Manual, Computer- and Robotic-Assisted Total Hip Arthroplasty.”
Image Credits: Hospital for Special Surgery
Keywords: Health and medicine
